A positive cervical or vaginal fetal fibronectin test at 22–24 weeks predicted more than half of the spontaneous preterm births at <28 weeks (sensitivity: 0.63). [42] The relative risk for a positive ...

Biomarker tests (PartoSure, Actim Partus and the Rapid fetal fibronectin [fFN] 10Q Cassette Kit) are intended for use with other clinical information to assess the risk of preterm birth in women with ...

A new app called QUiPP could help doctors to better identify women at risk of giving birth prematurely. The app, developed at King's College London, was tested in two studies of high-risk women being ...

The fetal fibronectin test: 25 years after its development, what is the evidence regarding its clinical utility? A systematic review and meta-analysis.

Three interventions and 2 comparators were included in this assessment. Actim Partus is a CE‑marked qualitative immunochromatographic point-of-care test designed to detect phosphorylated IGFBP‑1 ...